Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 12Genitourinary 6Plasma cell 4Lymphoid 3Breast 3Thoracic 2Head & Neck 2Gynecologic 2Other hematologic neoplasm 1Dermatologic 1

Conditions

Lymphoma 2571Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2058Leukemia, Lymphocytic, Chronic, B-Cell 1771Lymphoma, Follicular 1652Lymphoma, Large B-Cell, Diffuse 1597Leukemia 1172Hodgkin Disease 1128Lymphoma, Mantle-Cell 1110Burkitt Lymphoma 887Leukemia, Myeloid, Acute 885Lymphoma, B-Cell, Marginal Zone 788Recurrence 779Multiple Myeloma 744Lymphoma, B-Cell 704Myelodysplastic Syndromes 615Neoplasms 494Lymphoma, T-Cell, Cutaneous 479Waldenstrom Macroglobulinemia 470Lymphoma, Large-Cell, Immunoblastic 456Mycosis Fungoides 383Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 382Lymphoma, Large-Cell, Anaplastic 362Sezary Syndrome 321Lymphoma, T-Cell, Peripheral 321Leukemia, Myelogenous, Chronic, BCR-ABL Positive 307Hematologic Neoplasms 299Myeloproliferative Disorders 288Neoplasms, Plasma Cell 270Blast Crisis 261

Interventions

pembrolizumab 1cemiplimab 1blinatumomab 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Bites and Stings × Lymphoid × Clear all
NCT06022029 2025-12-24

ON-5001

OncoNano Medicine, Inc.

Phase 1 Recruiting
168 enrolled
BreastDermatologicGenitourinaryGynecologicHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Bites and Stings, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma in Situ, Uterine Cervical Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Skin Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Triple Negative Breast Neoplasms

NCT04609579 2024-01-30

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Stingthera, Inc.

Phase 1 Terminated
27 enrolled
GastrointestinalGynecologicLymphoid

Bites and Stings, Lymphoma, Ovarian Neoplasms, Colorectal Neoplasms, Lymphoma, B-Cell

NCT00274742 2015-01-16

Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

Amgen Research (Munich) GmbH

Phase 1 Completed
76 enrolled 15 charts
Lymphoid

Bites and Stings, Lymphoma, Non-Hodgkin, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡